CN104914092A - Pepsinogen II enzymatic chemiluminescence immunoassay kit - Google Patents
Pepsinogen II enzymatic chemiluminescence immunoassay kit Download PDFInfo
- Publication number
- CN104914092A CN104914092A CN201510268147.3A CN201510268147A CN104914092A CN 104914092 A CN104914092 A CN 104914092A CN 201510268147 A CN201510268147 A CN 201510268147A CN 104914092 A CN104914092 A CN 104914092A
- Authority
- CN
- China
- Prior art keywords
- solution
- monoclonal antibody
- enzyme
- pgii
- magnetic bead
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a pepsinogen II enzymatic chemiluminescence immunoassay kit and belongs to the technical field of chemiluminescence immunoassay analysis. The kit comprises an enzyme label liquid, a pepsinogen II standard, pepsinogen II monoclonal antibody-coated immunomagnetic beads, a sample diluent, a chemiluminescent substrate liquid and a washing liquid. The principle of the pepsinogen II enzymatic chemiluminescence immunoassay kit comprises that a pepsinogen II monoclonal antibody is connected to the surface of a magnetic bead so that a solid phase agent is obtained, and through capture of pepsinogen II in a sample and use of an enzyme-labeled anti-pepsinogen II monoclonal antibody, a solid phase-antibody-antigen-enzyme-labeled antibody sandwiched immune complex is formed. Through combination of a chemiluminescence technology and an immunomagnetic bead technology, the prepared kit has the advantages of high sensitivity, good specificity, wide linearity range and good stability and can satisfy clinical requirements on stomach function detection.
Description
Technical field
The invention belongs to technical field of immune assay, particularly relate to a kind of PGⅡ enzyme-catalyzed chemical luminescence detection kit.
Background technology
This test is for diagnosing severe atrophy body of stomach gastritis, and prompting early carcinoma of stomach risk.
Propepsin (Pesinogen, PG) is pepsic inactive precursor in gastric juice, by chief cell and the mucilage cell secretion of body of stomach.Major part is secreted into gastral cavity, can be detected in blood on a small quantity.PG II is secreted by the chief cell of the pyloric gland in stomach hole portion and the BrunnerShi glandular mucosa of duodenum near-end and neck cell.Pepsinogen Cgene (PGI) in serum or blood plasma is proportionate with the reduction of PG II ratio and the order of severity of corpus atrophy.In, severe atrophic gastritis time, its ratio is <3.0, and the incidence of disease of its cancer of the stomach significantly increases.Therefore, simultaneous determination PG I and PG II ratio can play the effect of early carcinoma of stomach indicating risk.
Chemiluminescence rise in eighties of last century be the eighties continue Enzyme-multiplied immune technique and the emerging technology that grows up after putting immune technology, due to its high sensitivity, high specific, while method is easy, quick, mark bond is stablized, without features such as emitting isotope damage and pollutions, obtaining develop rapidly in recent years.Chemiluminescent principle is the excited state intermediate of the instability generated in chemical reaction, when it gets back to ground state, and release photon.In immune detection is analyzed, use chemiluminescence, sensing range can be made to reach 6 orders of magnitude, and sensitivity is very high, add that label is stablized, the term of validity is long, makes it receive increasing concern and application.Magnetic particle separation enzyme-linked immunoassay technology is a kind of is solid phase carrier of separating with magnetic particle, immune magnetic particle isolation technics is combined with Enzyme-multiplied immune technique and a kind of Novel immune detection method of setting up.Conventional ELISA method, antigen, the association reaction of antibody carries out on solid phase (elisa plate reacting hole) surface, and Magneto separate enzyme-linked immune detection method, the association reaction of antigen, antibody also carries out under the condition of approximate liquid phase, and thus reaction fast, thoroughly.There is the advantage that automaticity is high, highly sensitive, the detection used time is few compared with traditional E LISA.But detect PG II kit in the market mainly based on traditional E LISA method.
Summary of the invention
The technical issues that need to address of the present invention are to provide a kind of PGⅡ enzyme-catalyzed chemical luminescence detection kit, make to achieve robotization, high specific and sensitivity to human pepsinogen II detection.
A kind of PGⅡ enzyme-catalyzed chemical luminescence detection kit, it is characterized in that, this kit comprises enzyme mark liquid, PGⅡ standard items, wraps by the immunomagnetic beads of PGⅡ monoclonal antibody, Sample dilution, Chemoluminescent substrate, cleansing solution.
Described method, it is characterized in that, PGⅡ monoclonal antibody is coated on magnetic bead microsphere surface by it, through catching PGⅡ in sample and after adding enzyme mark PGⅡ monoclonal antibody reagent, forming solid phase-antibody-antigene-enzyme labelled antibody sandwich immunoassay compound.
Described method, is characterized in that, described bag is the magnetic microsphere containing being marked with former II monoclonal antibody of antipepsin by the immunomagnetic beads of PGⅡ monoclonal antibody;
In described enzyme mark liquid, the enzyme of enzyme labelled antibody is horseradish peroxidase;
Described cleansing solution is the damping fluid containing Tween-20;
Described chemical luminous substrate solution is enzyme-catalyzed chemical luminescence substrate solution.
Let alone the kit described in, it is characterized in that, described bag is obtained as follows by the immunomagnetic beads of PGⅡ monoclonal antibody:
(1) preparation of first wash buffer:
Take the MES hygrate of 0.1952g in the pure water of 100ml, adjustment pH to 5.0;
Add 50 μ l Tween-20s, be made into 0.01mol/L MES damping fluid, adjustment pH to 5.0;
(2) preparation of coupling buffer:
Take 0.38138g Na
2b
4o
710H
2o is dissolved in 40ml pure water, obtains the borax soln of 0.05mol/L;
Take 0.1237g H
3bO
3be dissolved in 10ml pure water, obtain the BAS of 0.2mol/L;
Get the Na of 18ml 0.05mol/L
2b
4o
7the H of solution and 2ml 0.2mol/L
3bO
3solution mixes, and is settled to 80ml and obtains 0.05mol/L borate buffer;
(3) preparation of whole washing lotion:
Take 2.78g Na
2hPO
4be dissolved in 100ml pure water and obtain 0.2mol/L Na
2hPO
4solution;
Take 1.2g NaH
2pO
4be dissolved in 50ml pure water and obtain 0.2mol/L NaH
2pO
4solution;
Get 81ml 0.2mol/LNa
2hPO
4solution and 19ml 0.2mol/L NaH
2pO
4solution mixes, and obtains 0.2mol/L PB buffer solution and obtains 0.2mol/LPB buffer solution;
Get 50ml 0.2mol/L PB damping fluid, 2 times are diluted to 100ml, add 0.9gNaCl, and 0.5g0.5%-1%BSA, 0.02-0.03% biological preservative, 0.05% polysorbas20, fully dissolve mixing;
(4) preparation of confining liquid:
Get 100ml Tris damping fluid, the pH of solution is adjusted between 8.5-9.0;
Add 2%BSA wherein;
(5) preparation of EDC solution and NHS solution:
Take 1-(3-the dimethylamino-propyl)-3-ethyl carbodiimide of 25mg/ml, be dissolved in the first wash buffer of 1ml, be mixed with the EDC solution of 25mg/ml;
The N-hydroxy-succinamide taking 25mg/ml is dissolved in first wash buffer, is configured to 25mg/ml NHS solution;
(6) magnetic bead bag is by process:
A, previous cleaning: get 100 μ l magnetic beads, be diluted to the magnetic bead concentration of 10mg/ml, therefrom draw 100 μ l; Magneto separate frame is separated, removes supernatant; Wash three times, Magneto separate with first washing lotion 250 μ l, remove supernatant;
B, activation: get the magnetic bead that previous cleaning completes and add 150 μ lMES, then add the NHS solution of 50 μ l EDC and 50 μ l, fully mix.The lower 25 DEG C of activation 30min of room temperature, have activated Magneto separate and have removed supernatant, with the resuspended washing of 250 μ l coupling buffer three times, divided supernatant of leaving away;
C, dilute anti-G-17 monoclonal antibody:
Anti-G-17 monoclonal antibody taken out from-20 DEG C of refrigerators, after it melts, take out 20 μ l, be diluted to 400 μ l with coupling buffer 1:20, the antibody concentration after dilution is 0.0397mg/ml.
D, coupling:
Add the magnetic bead after the resuspended activation of anti-G-17 monoclonal antibody of 400 μ l coupling buffer dilutions, fully mix, its magnetic bead bag is 1mg magnetic bead by ratio: 0.0159mg antibody;
37 DEG C of coupling 2h, 37 DEG C of shaking tables rock constant temperature blending;
E, close:
Magnetic bead coupling terminated is separated on Magneto separate frame, removes supernatant;
Add 400 μ l confining liquids, 1h closed by 37 DEG C of shaking tables;
Close after terminating and remove supernatant;
F, wash preservation eventually:
With the magnetic bead that the whole wash liquid of 400 μ l has been closed, in triplicate, final constant volume is to 500 μ l.
Principle of work of the present invention is a kind of detection method that double antibody sandwich method chemiluminescence combines with immunomagnetic bead technique.In sample, add quantitative bag marked anti-PG II monoclonal antibody by the immunomagnetic beads of PGⅡ monoclonal antibody and HRP.37 DEG C hatch after, wrap by the immunomagnetic beads of PGⅡ monoclonal antibody and HRP mark anti-PG II monoclonal antibody respectively in sample the different epi-positions of PG II molecule be combined, form magnetic bead-antibody-antigen-antibody compound.Direct precipitation in externally-applied magnetic field, namely separable.Abandoning supernatant, the compound of washing and precipitating, then adds enzyme-catalyzed chemical luminescence substrate.Substrate is catalytic pyrolysis under the effect of enzyme, form unstable excited state intermediate, just have issued photon when excited state intermediate gets back to ground state, form luminescence-producing reaction, the luminous intensity of light-emitting appearance detection reaction can be used, PG II content in sample can be calculated according to typical curve.In sensing range, luminous intensity is directly proportional to PG II concentration in sample.
The invention is characterized in: the method detecting PGⅡ in serum employs following reagent:
The present invention use enzyme mark liquid for HRP marks anti-PG II monoclonal antibody.
PGⅡ standard items of the present invention are the BSA protein solutions containing a certain amount of PG II antigen.
Sample dilution contained by the present invention is the PBS solution containing 1%BSA.
Chemoluminescent substrate of the present invention is enzyme-catalyzed chemical luminescence substrate solution.
Cleansing solution of the present invention is the damping fluid containing Tween-20 and ProCline-300.
PGⅡ enzyme-catalyzed chemical luminescence detection kit method of operating of the present invention is as follows:
One, magnetic bead bag is buffered liquid preparation:
1. the preparation of first wash buffer:
1.1 take the MES hygrate of 0.1952g in the pure water of 100ml, adjustment pH to 5.0
1.2 add 50 μ l Tween-20s, are made into 0.01mol/L MES damping fluid, adjustment pH to 5.0.
2. the preparation of coupling buffer:
2.1 take 0.38138g Na
2b
4o
710H
2o is dissolved in 40ml pure water, obtains the borax soln of 0.05mol/L.
2.2 take 0.1237g H
3bO
3be dissolved in 10ml pure water, obtain the BAS of 0.2mol/L
2.3 Na getting 18ml 0.05mol/L
2b
4o
7the H of solution and 2ml 0.2mol/L
3bO
3solution mixes, and is settled to 80ml and obtains 0.05mol/L borate buffer
3. the preparation of whole washing lotion:
3.1 take 2.78g Na
2hPO
4be dissolved in 100ml pure water and obtain 0.2mol/L Na
2hPO
4solution.
3.2 take 1.2g NaH
2pO
4be dissolved in 50ml pure water and obtain 0.2mol/L NaH
2pO
4solution.
3.3 get 81ml 0.2mol/LNa
2hPO
4solution and 19ml 0.2mol/L NaH
2pO
4solution mixes, and obtains 0.2mol/L PB buffer solution and obtains 0.2mol/LPB buffer solution.
3.3 get 50ml 0.2mol/L PB damping fluid, and 2 times are diluted to 100ml, add 0.9g NaCl, and 0.5g0.5%-1%BSA, 0.02-0.03% biological preservative, 0.05% Tween-20, fully dissolve mixing.
4. the preparation of confining liquid:
4.1 get 100ml Tris damping fluid, during the pH of solution is adjusted to 8.5-9.0.
4.2 add 2%BSA to it
The preparation of 5.EDC solution and NHS solution
5.1 1-(3-the dimethylamino-propyl)-3-ethyl carbodiimide taking 25mg/ml, are dissolved in the first wash buffer of 1ml, are mixed with the EDC solution of 25mg/ml.
5.2 N-hydroxy-succinamides taking 25mg/ml are dissolved in first wash buffer, are configured to 25mg/mlNHS solution
Two, magnetic bead bag is by process
1. previous cleaning:
1.1 get 100 μ l magnetic beads, are diluted to the magnetic bead concentration of 10mg/ml, therefrom draw 100 μ l.
1.2 Magneto separate framves are separated, remove supernatant.
1.3 wash three times, Magneto separate with first washing lotion 250 μ l, remove supernatant.
2. activate:
2.1 get the magnetic bead that previous cleaning completes adds 150 μ l MES, then adds the NHS solution of 50 μ l EDC and 50 μ l, fully mixes.The lower 25 DEG C of activation 30min of room temperature.
2.2 have activated Magneto separate removes supernatant, with the resuspended washing of 250 μ l coupling buffer three times, divides supernatant of leaving away.
3. dilute anti-PG II monoclonal antibody:
Anti-PG II monoclonal antibody taken out from-20 DEG C of refrigerators, after it melts, take out 40 μ l, be diluted to 400 μ l with coupling buffer 1:10, the antibody concentration after dilution is 0.0847mg/ml.Its magnetic bead bag is 1mg magnetic bead by ratio: 0.0338mg antibody.
4. coupling:
4.1 add 400 μ l coupling buffers dilution the resuspended activation of anti-PG II monoclonal antibody after magnetic bead, fully mix.
4.237 DEG C of coupling 2h, 37 DEG C of shaking tables rock constant temperature blending.
5. close:
5.1 magnetic beads coupling terminated are separated on Magneto separate frame, remove supernatant.
5.2 add 400 μ l confining liquids, and 1h closed by 37 DEG C of shaking tables.
Supernatant is removed after 5.3 closed end.
6. wash preservation eventually:
6.1 magnetic beads closed with the whole wash liquid of 400 μ l, in triplicate.
6.3 final constant volumes, to 250 μ l, are diluted to 500 μ l and use during use.
Three, Sample dilution preparation
NaH is added in purified water
2pO
4, Na
2hPO
4, preparation 100ml phosphate buffer, add casein, Tween-20, ProClin 300, orchil, regulate pH value to 7.4-7.6.
Four, the preparation of PGⅡ standard items
Preparing 4 bottles of PG II standard items, is antiseptic containing 0.1%ProCline 300.The concentration often criticizing PG II titer in kit is 5.6 μ g/L, 11.9 μ g/L, 30.5 μ g/L, 54.1 μ g/L.
Five, the preparation of enzyme mark liquid
Preparation 15mL HRP marks anti-PG II monoclonal antibody, is kept at 0.02%methylosothiazolone, in 0.02%bromonitrodioxne stabilizing agent and 0.002%active isothiazoloneization antiseptic.
Six, the preparation of cleansing solution
The concentrated phosphoric acid salt buffer of preparation 20ml (using after 20 times of dilutions) is antiseptic containing Tween-20 and 0.1%ProCline-300
Seven, the configuration of substrate solution
1. prepare substrate buffer solution
1.1 take 4.542gTris, take 0.458g sodium borate, and constant volume, to 300ml, regulates pH to 8.7-9.0.
2. prepare substrate A liquid
2.1 take 0.023g carbamide peroxide, take 0.024g 4-Morpholinopyridine (stabilizing agent).
2.2 add sodium borate buffer liquid constant volume to 100ml with Tris-HCl, room temperature preservation.
3. prepare substrate B liquid
3.1 take 0.088g luminol, take 0.051g 3-(10-phenothiazinyl) propane-1-sulfonate.
3.2 add sodium borate buffer liquid constant volume to 100ml with Tris-HCl.
The B liquid prepared wraps up with masking foil by 3.3, room temperature preservation.
Eight, kit provided by the invention, comprises following component:
| Reagent name | Loading amount | Use-pattern |
| Bag is by the immunomagnetic beads of PGⅡ monoclonal antibody | 3ml | Direct use |
| Cleansing solution | 20ml | Use after 20 times of dilutions |
| Sample dilution | 100ml | Direct use |
| PGⅡ standard items | 1.5ml, 3 bottles | Direct use |
| Enzyme mark liquid | 15ml | Direct use |
| Chemoluminescent substrate | 15ml | Direct use |
The present invention has following innovation:
1. the invention provides a kind of PGⅡ chemiluminescence detection kit, the diagnosis of corpus atrophy gastritis can be assisted, and the incidence of assessment canceration.
2. the capture antibody used and enzyme labelled antibody are monoclonal antibody, and be that the affinity of reaction is higher, non-specific adsorption reduces, and the production differences between batches of monoclonal antibody are relatively little, more easily ensure product batch between stable.
Accompanying drawing explanation
The Trendline of the values of chemiluminescence that Fig. 1: 1mg magnetic bead bag is obtained by PG II antigen for variable concentrations after 0.0338mgPG II monoclonal antibody.
Embodiment
The first step: wrap by the preparation of the immunomagnetic beads of PGⅡ monoclonal antibody
One, the preparation of magnetic bead activation buffer:
1. the preparation of first wash buffer:
1.1 take the MES hygrate of 0.1952g in the pure water of 100ml, adjustment pH to 5.0.
1.2 add 50 μ l Tween-20s, are made into 0.01mol/L MES damping fluid, adjustment pH to 5.0.
2. the preparation of coupling buffer:
2.1 take 0.38138g Na
2b
4o
710H
2o is dissolved in 40ml pure water, obtains the borax soln of 0.05mol/L.
2.2 take 0.1237g H
3bO
3be dissolved in 10ml pure water, obtain the BAS of 0.2mol/L.
2.3 Na getting 18ml 0.05mol/L
2b
4o
7the H of solution and 2ml 0.2mol/L
3bO
3solution mixes, and is settled to 80ml and obtains 0.05mol/L borate buffer.
3. the preparation of whole washing lotion:
3.1 take 2.78g Na
2hPO
4be dissolved in 100ml pure water and obtain 0.2mol/L Na
2hPO
4solution.
3.2 take 1.2g NaH
2pO
4be dissolved in 50ml pure water and obtain 0.2mol/L NaH
2pO
4solution.
3.3 get 81ml 0.2mol/LNa
2hPO
4solution and 19ml 0.2mol/L NaH
2pO
4solution mixes, and obtains 0.2mol/L PB buffer solution and obtains 0.2mol/LPB buffer solution.
3.3 get 50ml 0.2mol/L PB damping fluid, and 2 times are diluted to 100ml, add 0.9gNaCl, and 0.5gBSA (0.5%-1% adjustment) 0.02-0.03% biological preservative, 0.05% Tween-20, fully dissolve mixing.
4. the preparation of confining liquid:
4.1 get 100ml Tris damping fluid, during the pH of solution is adjusted to 8.5-9.0.
4.2 add 2%BSA to it.
The preparation of 5.EDC solution and NHS solution:
5.1 1-(3-the dimethylamino-propyl)-3-ethyl carbodiimide taking 25mg/ml, are dissolved in the first wash buffer of 1ml, are mixed with the EDC solution of 25mg/ml.
5.2 N-hydroxy-succinamides taking 25mg/ml are dissolved in first wash buffer, are configured to 25mg/ml NHS solution.
Two, the operation steps of magnetic bead activation buffer:
1. previous cleaning:
1.1 get 100 μ l magnetic beads, are diluted to the magnetic bead concentration of 10mg/ml, therefrom draw 100 μ l.
1.2 Magneto separate framves are separated, remove supernatant.
1.3 wash three times, Magneto separate with first washing lotion 250 μ l, remove supernatant.
2. activate:
2.1 get the magnetic bead that previous cleaning completes adds 150 μ l MES, then adds the NHS solution of 50 μ l EDC and 50 μ l, fully mixes.The lower 25 DEG C of activation 30min of room temperature.
2.2 have activated Magneto separate removes supernatant, with the resuspended washing of 250 μ l coupling buffer three times, divides supernatant of leaving away.
3. dilute anti-PG II monoclonal antibody:
Anti-PG II monoclonal antibody taken out from-20 DEG C of refrigerators, after it melts, take out 40 μ l, be diluted to 400 μ l with coupling buffer 1:10, the antibody concentration after dilution is 0.0847mg/ml.Its magnetic bead bag is 1mg magnetic bead by ratio: 0.0338mg antibody.
4. coupling
4.1 add 400 μ l coupling buffers dilution the resuspended activation of anti-PG II monoclonal antibody after magnetic bead, fully mix.
4.237 DEG C of coupling 2h, 37 DEG C of shaking tables rock constant temperature blending.
5. close
5.1 magnetic beads coupling terminated are separated on Magneto separate frame, remove supernatant.
5.2 add 400 μ l confining liquids, and 1h closed by 37 DEG C of shaking tables.
Supernatant is removed after 5.3 closed end.
6. wash preservation eventually
6.1 magnetic beads closed with the whole wash liquid of 400 μ l, in triplicate.
6.3 final constant volumes, to 250 μ l, are diluted to 500 μ l during use.
Second step: Sample dilution is prepared
NaH is added in purified water
2pO
4, Na
2hPO
4, preparation 100ml phosphate buffer, add bovine serum albumin, Tween-20, ProClin 300, orchil, regulate pH value to 7.4-7.6.
3rd step: the preparation of PGⅡ standard items
Preparing 4 bottles of PG II standard items, is antiseptic containing 0.1%ProCline 300.The concentration often criticizing PG II titer in kit is 5.6 μ g/L, 11.9 μ g/L, 30.5 μ g/L, 54.1 μ g/L.
4th step: the preparation of enzyme mark liquid
Preparation 15mL HRP marks anti-PG II monoclonal antibody, is kept at 0.02%methylosothiazolone, in 0.02%bromonitrodioxne stabilizing agent and 0.002%active isothiazoloneization antiseptic.
5th step: the preparation of cleansing solution
The concentrated phosphoric acid salt buffer of preparation 20ml (using after 20 times of dilutions) is antiseptic containing Tween-20 and 0.1%ProCline-300.
6th step: the configuration of substrate solution
1. prepare substrate buffer solution
1.1 take 4.542g Tris, take 0.458g sodium borate, and constant volume, to 300ml, regulates pH to 8.7-9.0.
2. prepare substrate A liquid
2.1 take 0.023g carbamide peroxide, take 0.024g 4-Morpholinopyridine (stabilizing agent).
2.2 add sodium borate buffer liquid constant volume to 100ml with Tris-HCl, room temperature preservation.
3. prepare substrate B liquid
3.1 take 0.088g luminol, take 0.051g 3-(10-phenothiazinyl) propane-1-sulfonate (reinforcing agent).
3.2 add sodium borate buffer liquid constant volume to 100ml with Tris-HCl.
The B liquid prepared wraps up with masking foil by 3.3, room temperature preservation.
7th step: the present invention's Full-automatic chemiluminescence detecting instrument detection mode is as follows:
1. instrument washing
10 ~ 15 washings are carried out to the measuring chamber of instrument and cleaning station, treat that its background value declines, and the measurement of substrate luminous value reaches steady, measurement can be started.
2. application of sample and immune response
2.1 by the magnetic bead of q.s, and enzyme mark anti-PG II antibody adds in the kit of Full-automatic chemiluminescence detector successively.
2.2 add 50-100 μ l serum or plasma sample standard items in 4ml test tube, put into the sample disk of Full-automatic chemiluminescence apparatus device successively.
2.3 primary first-order equations draw 30 μ l PG II antibody magnetic bead reagent, and enzyme labelled antibody once adds 100 μ l, and antigen titer adds 80 μ l.Mix rear 37 DEG C of incubation 30min.
3. start instrument, detect whole process and comprise: application of sample, hatch, washing, measure.
4. washing reaction cup: mechanical arm by incubation slot reaction cup clip to the cleaning station of automation illumination instrument, be magnetic-adsorption under cleaning station groove, instrument suction nozzle is drawn by supernatant, and a tube head is ejection cleansing solution, and cleaning disc turns around common washing 6 times.
7., after application of sample terminates, after 37 DEG C of incubation grooves hatch 30min, reaction cup is clipped to cleaning station by mechanical arm, washing reaction cup: be magnetic-adsorption under cleaning station groove, instrument suction nozzle is drawn by supernatant, and tube head is ejection cleansing solution, and cleaning disc turns around common washing 6 times.
8. add luminous substrate working fluid: add 100 μ l substrate solutions in two first backward reaction cup of needle tubing, prepare to measure after hatching 100s.
9. read luminous value: transfer to measuring chamber by reaction cup from cleaning station, measure, obtain numerical value.
8th step: clinical sample detects
1. detection scheme
It is human serum or blood plasma that this reagent detects sample.
Take a blood sample and within first 10 hours, should keep on an empty stomach.Gather venous samples can to if any in EDTA plastic tube or non-additive serum plastic test tube.The test tube of blood plasma should turn upside down test tube 5 ~ 6 times in time to mix sample.When test sample book is serum, condensation (at least 30 minutes) need be placed at room temperature (20 ~ 25 DEG C).Serum condenses afterwards and blood plasma uses centrifugal method (as with plastic test tube, accelerating to 2000G, centrifugal 10 ~ 15 minutes) to be separated immediately.Plasma/serum sample can refrigerate in refrigerator (2 ~ 8 DEG C), as needed the storage of longer time should freezing (being suitable for-70 ~-20 DEG C of storages).Sample should mix after thawing.Avoid multigelation.Avoid using containing hemolysin, grease or dirty impure sample.
Sample picks up from the normal health check-up of 1000 example, blood donor.Serum sample physical examination result is all without liver, brain, kidney, disease of digestive tract, and without transfusion and major operation history in half a year, women is not in the gestational period and lactation.Measured value is carried out statistical analysis, draws normal serum term of reference: PG II is 3 ~ 15 μ g/L.
2. kit performance index of the present invention
Sensitivity: minimumly detect value 0.1 μ g/L; Accuracy: variation within batch CV%<7.5%, batch variation CV%<9.4%; Specificity: with the cross reaction of pepsinogen I lower than 5%; Linear coefficient: r>0.9900; The range of linearity: 2.5 ~ 40 μ g/L.
Wherein Fig. 1 is the Trendline of the values of chemiluminescence that 1mg magnetic bead bag is obtained by PG II antigen for variable concentrations after 0.0338mgPG II monoclonal antibody.
Claims (4)
1. a PGⅡ enzyme-catalyzed chemical luminescence detection kit, it is characterized in that, this kit comprises enzyme mark liquid, PGⅡ standard items, wraps by the immunomagnetic beads of PGⅡ monoclonal antibody, Sample dilution, Chemoluminescent substrate, cleansing solution.
2. according to PGⅡ enzyme-catalyzed chemical luminescence detection kit according to claim 1, it is characterized in that, PGⅡ monoclonal antibody is coated on magnetic bead microsphere surface by it, through catching PGⅡ in sample and after adding enzyme mark PGⅡ monoclonal antibody reagent, forming solid phase-antibody-antigene-enzyme labelled antibody sandwich immunoassay compound.
3. according to PGⅡ enzyme-catalyzed chemical luminescence detection kit according to claim 1, it is characterized in that, described bag is the magnetic microsphere containing being marked with former II monoclonal antibody of antipepsin by the immunomagnetic beads of PGⅡ monoclonal antibody;
In described enzyme mark liquid, the enzyme of enzyme labelled antibody is horseradish peroxidase;
Described cleansing solution is the damping fluid containing Tween-20;
Described chemical luminous substrate solution is enzyme-catalyzed chemical luminescence substrate solution.
4. as claim 1-2 lets alone the kit as described in, it is characterized in that, described bag is obtained as follows by the immunomagnetic beads of PGⅡ monoclonal antibody:
(1) preparation of first wash buffer:
Take the MES hygrate of 0.1952g in the pure water of 100ml, adjustment pH to 5.0;
Add 50 μ l Tween-20s, be made into 0.01mol/L MES damping fluid, adjustment pH to 5.0;
(2) preparation of coupling buffer:
Take 0.38138g Na
2b
4o
710H
2o is dissolved in 40ml pure water, obtains the borax soln of 0.05mol/L;
Take 0.1237g H
3bO
3be dissolved in 10ml pure water, obtain the BAS of 0.2mol/L;
Get the Na of 18ml 0.05mol/L
2b
4o
7the H of solution and 2ml 0.2mol/L
3bO
3solution mixes, and is settled to 80ml and obtains 0.05mol/L borate buffer;
(3) preparation of whole washing lotion:
Take 2.78g Na
2hPO
4be dissolved in 100ml pure water and obtain 0.2mol/L Na
2hPO
4solution;
Take 1.2g NaH
2pO
4be dissolved in 50ml pure water and obtain 0.2mol/L NaH
2pO
4solution;
Get 81ml 0.2mol/LNa
2hPO
4solution and 19ml 0.2mol/L NaH
2pO
4solution mixes, and obtains 0.2mol/L PB buffer solution and obtains 0.2mol/LPB buffer solution;
Get 50ml 0.2mol/L PB damping fluid, 2 times are diluted to 100ml, add 0.9gNaCl, and 0.5g0.5%-1%BSA, 0.02-0.03% biological preservative, 0.05% polysorbas20, fully dissolve mixing;
(4) preparation of confining liquid:
Get 100ml Tris damping fluid, the pH of solution is adjusted between 8.5-9.0;
Add 2%BSA wherein;
(5) preparation of EDC solution and NHS solution:
Take the EDC of 25mg/ml, be dissolved in the first wash buffer of 1ml, be mixed with the EDC solution of 25mg/ml;
The N-hydroxy-succinamide taking 25mg/ml is dissolved in first wash buffer, is configured to 25mg/ml NHS solution;
(6) magnetic bead bag is by process:
A, previous cleaning: get 100 μ l magnetic beads, be diluted to the magnetic bead concentration of 10mg/ml, therefrom draw 100 μ l; Magneto separate frame is separated, removes supernatant; Wash three times, Magneto separate with first washing lotion 250 μ l, remove supernatant;
B, activation: get the magnetic bead that previous cleaning completes and add 150 μ lMES, then add the NHS solution of 50 μ l EDC and 50 μ l, fully mix; The lower 25 DEG C of activation 30min of room temperature, have activated Magneto separate and have removed supernatant, with the resuspended washing of 250 μ l coupling buffer three times, divided supernatant of leaving away;
C, dilute anti-G-17 monoclonal antibody:
Anti-G-17 monoclonal antibody taken out from-20 DEG C of refrigerators, after it melts, take out 20 μ l, be diluted to 400 μ l with coupling buffer 1:20, the antibody concentration after dilution is 0.0397mg/ml;
D, coupling:
Add the magnetic bead after the resuspended activation of anti-G-17 monoclonal antibody of 400 μ l coupling buffer dilutions, fully mix, its magnetic bead bag is 1mg magnetic bead by ratio: 0.0159mg antibody;
37 DEG C of coupling 2h, 37 DEG C of shaking tables rock constant temperature blending;
E, close:
Magnetic bead coupling terminated is separated on Magneto separate frame, removes supernatant;
Add 400 μ l confining liquids, 1h closed by 37 DEG C of shaking tables;
Close after terminating and remove supernatant;
F, wash preservation eventually:
With the magnetic bead that the whole wash liquid of 400 μ l has been closed, in triplicate, final constant volume is to 500 μ l.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510268147.3A CN104914092A (en) | 2015-05-22 | 2015-05-22 | Pepsinogen II enzymatic chemiluminescence immunoassay kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510268147.3A CN104914092A (en) | 2015-05-22 | 2015-05-22 | Pepsinogen II enzymatic chemiluminescence immunoassay kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104914092A true CN104914092A (en) | 2015-09-16 |
Family
ID=54083345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510268147.3A Pending CN104914092A (en) | 2015-05-22 | 2015-05-22 | Pepsinogen II enzymatic chemiluminescence immunoassay kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104914092A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106018388A (en) * | 2016-05-18 | 2016-10-12 | 威海威高生物科技有限公司 | Kit for testing PG (pepsinogen) I or II and preparation method of kit |
| CN109307765A (en) * | 2018-11-29 | 2019-02-05 | 郑州安图生物工程股份有限公司 | Type pepsinogen II detection kit |
| CN109444406A (en) * | 2018-11-09 | 2019-03-08 | 深圳市众循精准医学研究院 | Test strips of quantitative detection marker cyfra21-1 and preparation method thereof and detection method |
| CN110208547A (en) * | 2019-06-27 | 2019-09-06 | 北京柏海达科技有限公司 | A kind of propepsin immunochromatographytest test kit and preparation method thereof based on carbon quantum dot |
| CN112147328A (en) * | 2020-08-31 | 2020-12-29 | 浙江博实生物科技有限公司 | Immunoassay kit based on pepsinogen PG I, and preparation method and detection method thereof |
| CN112147333A (en) * | 2020-08-31 | 2020-12-29 | 浙江博实生物科技有限公司 | Immunoassay kit based on pepsinogen PG II, and preparation method and detection method thereof |
| CN113533733A (en) * | 2021-07-14 | 2021-10-22 | 上海交通大学 | Chemiluminescence immunoassay kit for detecting AEP protein level in human blood |
| CN114252595A (en) * | 2021-12-23 | 2022-03-29 | 武汉生之源生物科技股份有限公司 | Magnetic bead diluent and immunoassay kit for reducing sample matrix interference |
| CN114805586A (en) * | 2022-04-14 | 2022-07-29 | 天津华科泰生物技术有限公司 | anti-MxA monoclonal antibody composition and application thereof |
| CN116840487A (en) * | 2023-05-30 | 2023-10-03 | 中拓生物有限公司 | Method for detecting sugar-deficient transferrin |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0737863A1 (en) * | 1993-12-28 | 1996-10-16 | Ss Pharmaceutical Co., Ltd. | Method of detecting blood constituent and kit therefor |
| CN1975423A (en) * | 2006-09-06 | 2007-06-06 | 浙江清华长三角研究院 | Immuno magnetic bead and producing method, and method and test plate for detection |
| CN102426236A (en) * | 2011-08-31 | 2012-04-25 | 内蒙古科慧生物科技有限责任公司 | Pepsinogen II (PGII) quantitative determination kit and detection method thereof |
| CN104034892A (en) * | 2014-06-23 | 2014-09-10 | 广西博士海意信息科技有限公司 | Magnetic particle chemiluminescence immune assay kit of tumor marker AFP (alpha fetal protein) and detection method thereof |
-
2015
- 2015-05-22 CN CN201510268147.3A patent/CN104914092A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0737863A1 (en) * | 1993-12-28 | 1996-10-16 | Ss Pharmaceutical Co., Ltd. | Method of detecting blood constituent and kit therefor |
| CN1975423A (en) * | 2006-09-06 | 2007-06-06 | 浙江清华长三角研究院 | Immuno magnetic bead and producing method, and method and test plate for detection |
| CN102426236A (en) * | 2011-08-31 | 2012-04-25 | 内蒙古科慧生物科技有限责任公司 | Pepsinogen II (PGII) quantitative determination kit and detection method thereof |
| CN104034892A (en) * | 2014-06-23 | 2014-09-10 | 广西博士海意信息科技有限公司 | Magnetic particle chemiluminescence immune assay kit of tumor marker AFP (alpha fetal protein) and detection method thereof |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106018388A (en) * | 2016-05-18 | 2016-10-12 | 威海威高生物科技有限公司 | Kit for testing PG (pepsinogen) I or II and preparation method of kit |
| CN106018388B (en) * | 2016-05-18 | 2019-01-11 | 威海威高生物科技有限公司 | A kind of pepsinogen Cgene or II assay kit and preparation method thereof |
| CN109444406A (en) * | 2018-11-09 | 2019-03-08 | 深圳市众循精准医学研究院 | Test strips of quantitative detection marker cyfra21-1 and preparation method thereof and detection method |
| CN109307765A (en) * | 2018-11-29 | 2019-02-05 | 郑州安图生物工程股份有限公司 | Type pepsinogen II detection kit |
| CN110208547B (en) * | 2019-06-27 | 2022-07-08 | 北京柏海达科技有限公司 | Pepsinogen immunochromatography detection kit based on carbon quantum dots and preparation method thereof |
| CN110208547A (en) * | 2019-06-27 | 2019-09-06 | 北京柏海达科技有限公司 | A kind of propepsin immunochromatographytest test kit and preparation method thereof based on carbon quantum dot |
| CN112147328A (en) * | 2020-08-31 | 2020-12-29 | 浙江博实生物科技有限公司 | Immunoassay kit based on pepsinogen PG I, and preparation method and detection method thereof |
| CN112147333A (en) * | 2020-08-31 | 2020-12-29 | 浙江博实生物科技有限公司 | Immunoassay kit based on pepsinogen PG II, and preparation method and detection method thereof |
| CN113533733A (en) * | 2021-07-14 | 2021-10-22 | 上海交通大学 | Chemiluminescence immunoassay kit for detecting AEP protein level in human blood |
| CN114252595A (en) * | 2021-12-23 | 2022-03-29 | 武汉生之源生物科技股份有限公司 | Magnetic bead diluent and immunoassay kit for reducing sample matrix interference |
| CN114805586A (en) * | 2022-04-14 | 2022-07-29 | 天津华科泰生物技术有限公司 | anti-MxA monoclonal antibody composition and application thereof |
| CN116840487A (en) * | 2023-05-30 | 2023-10-03 | 中拓生物有限公司 | Method for detecting sugar-deficient transferrin |
| CN116840487B (en) * | 2023-05-30 | 2024-03-19 | 中拓生物有限公司 | Method for detecting sugar-deficient transferrin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104914092A (en) | Pepsinogen II enzymatic chemiluminescence immunoassay kit | |
| CN104914251A (en) | Gastrin-17 enzymatic chemiluminescence immunoassay kit | |
| CN104965077A (en) | Pepsinogen I enzymatic chemiluminescence detection kit | |
| CN101949942B (en) | Kit for quantitatively testing free triiodothyronine | |
| CN109991409B (en) | Pepsinogen I/pepsinogen II detection kit | |
| CN103063851B (en) | Free triiodothyronine nanometer magnetic particle chemiluminescence assay kit and preparation method thereof and detection method thereof | |
| CN108445230B (en) | Procalcitonin chemiluminescence detection reagent based on nano antibody and detection method | |
| CN104502591A (en) | Pepsinogen I and II combined detection method and kit thereof | |
| CN105785043A (en) | Kit for quantitatively detecting AFP-L3% | |
| WO2019148837A1 (en) | Magnetic particle reagent and kit for chemiluminescence immunoassay | |
| CN101949945B (en) | Kit for detecting free thyroxin by using magnetic particles as solid-phase carriers and preparation method thereof | |
| CN105067599A (en) | Chemiluminescence immune detection kit for detecting pro-gastrin-releasing peptide | |
| CN101377513A (en) | Chromogranin A chemiluminescence immune analysis quantitative determination reagent kit and preparing method thereof | |
| CN202916286U (en) | Latex enhanced turbidimetric immunoassay kit for quantitatively detecting procalcitonin (PCT) | |
| CN104502592A (en) | Pepsinogen II detection method and kit thereof | |
| CN103197077A (en) | Assay kit for detecting trace bovine immunoglobulin G | |
| CN113514449A (en) | Application of kit for detecting serum amyloid A by using space proximity chemiluminescence method and detection method | |
| CN107782902A (en) | A kind of myoglobins monoclonal antibody enzyme combination compound and the kit for detecting myoglobin content containing it | |
| CN107328933A (en) | Magnetic particle enhancing immunoturbidimetry detection box and its application | |
| WO2021000654A1 (en) | Method for detecting heparin or heparin-like substances in blood and kit | |
| CN103063852A (en) | Free thyroxine nanometer magnetic particle chemiluminescence assay kit and preparation method thereof and detection method thereof | |
| CN106802345B (en) | A kind of helicobacter pylori IgG antibody enzyme-linked immunologic diagnosis kit | |
| CN113238055A (en) | Kit for detecting procalcitonin by using space proximity chemiluminescence method, and detection method and application thereof | |
| CN107727861B (en) | A kind of pepsin assay kit and measuring method | |
| CN104777317B (en) | The preparation of a kind of gold nanoparticle probe and the application in tachysynthesis detects thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150916 |
|
| RJ01 | Rejection of invention patent application after publication |